AI is changing how cancer care decisions are made, empowering patients and doctors to make more personalized choices. For ...
AI in Pathology Market OverviewThe global AI in pathology market is anticipated to witness robust expansion, growing at an estimated compound annual growth rate of around 26% during the forecast ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
The phase 2 ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT-PC) trial tested a cooled laser focal therapy device for intermediate-risk prostate cancer treatment.
A novel, cooled laser focal therapy (cLFT) exhibits high treatment success for localized prostate cancer (PCa), according to a study published online Jan. 28 in ...
The field of pathology is rapidly evolving toward the integration of molecular and cellular levels, immunology, and digital advances to better understand ...
AI in oncology is poised to revolutionize cancer care through early, accurate detection, and personalized treatment, driven ...
Gut Microbiota and Benign Prostatic Hyperplasia research highlights new inflammatory pathways and microbiome targets. Learn ...
Explore how biochemistry, microbiology, and pathology collaborate in cancer care for early detection, personalized treatment, and survival monitoring.
In explaining the rationale behind the study, Tang and colleagues pointed out that despite the lack of level 1 evidence, MDT ...
Bone marrow metastasis (BMM) from non-hematolymphoid malignancies with resultant cytopenia(s) can mimic primary hematolymphoid disorders. This study ...
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results